Tharimmune (NASDAQ:THAR) Stock Price Down 2.3% – Here’s Why

Tharimmune, Inc. (NASDAQ:THAR)’s share price traded down 2.3% during trading on Monday . The company traded as low as $1.65 and last traded at $1.69. 109,430 shares changed hands during trading, a decline of 71% from the average session volume of 371,942 shares. The stock had previously closed at $1.73.

Tharimmune Price Performance

The business has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $1.60. The firm has a market cap of $4.50 million, a price-to-earnings ratio of -0.21 and a beta of 1.21.

Tharimmune (NASDAQ:THAR) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.15).

Insider Activity at Tharimmune

In related news, CEO Sireesh Appajosyula purchased 61,496 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average price of $1.48 per share, with a total value of $91,014.08. Following the completion of the acquisition, the chief executive officer owned 64,868 shares in the company, valued at $96,004.64. This trade represents a 1,823.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Gravitas Capital Lp purchased 337,838 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The stock was bought at an average cost of $1.48 per share, with a total value of $500,000.24. Following the acquisition, the chairman owned 732,424 shares of the company’s stock, valued at approximately $1,083,987.52. The trade was a 85.62% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 400,334 shares of company stock valued at $592,464. Insiders own 10.01% of the company’s stock.

Institutional Investors Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned about 1.11% of Tharimmune as of its most recent SEC filing. Institutional investors and hedge funds own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).